ENOSIUM-LIFE-SCI/OTIUM
5.3.2024 10:01:27 CET | Business Wire | Press release
Dr Antoine Amer, supported by Otium Capital, announced the creation of Enosium Life Science, a group poised to redefine services in the healthcare market by acquiring and combining best-in-class life science experts in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305557434/en/
Enosium Life Science aims to be a key advisory and scientific services provider for pharmaceuticals, biotech and medtech firms from clinical development to commercialisation. Antoine Amer brings 20+ years of global pharmaceutical leadership experience in launching and growing healthcare innovations.
A Multi-Specialist European Group Dedicated to Life Sciences
Enosium Life Science combines local knowledge, scientific expertise, entrepreneurial agility, and international standards to address critical challenges facing pharmaceutical companies.
Enosium Life Science will implement a targeted acquisition strategy, focusing on service providers in: clinical research (CRO), regulatory affairs, market access, medical affairs, and marketing, to offer an end-to-end continuum of science-based services.
Antoine Amer, Enosium Life Science CEO, commented, "Our vision is to combine the best expertise across Europe, providing a unique and comprehensive range of scientific services to address growing complexities in the European healthcare ecosystem, which will enable faster and broader access to medical innovations for patients."
François Durvye, Otium Capital CEO, added, "Investing in Enosium Life Science demonstrates our commitment to supporting innovation and excellence in this key field. Led by Antoine Amer, Enosium Life Science aims to address the major challenges in medical innovations and improving patients’ health and quality of life."
About Enosium Life Science:
Enosium Life Science is an integrated group of scientific services for the European life sciences market. Providing comprehensive expertise from clinical development to commercialisation (clinical research, regulatory affairs, market access, medical affairs, marketing), Enosium Life Science is committed to becoming the partner-of-choice for healthcare industries, and to address the critical challenges facing pharma, biotech and medtech companies.
About Otium Capital:
Otium Capital is a major player in private investment in France with €1.5 billion in assets under management. Serving as the Family Office for French entrepreneur and founder of Smartbox Pierre-Edouard Stérin, Otium Capital invests across various domains. With significant experience in healthcare (Owkin, Hapni, Okomera, etc.) and expertise in buy-and-build strategies (Otium Leisure, Novavet, Otelium, Alfeor), Otium Capital is a key player in fostering innovation and growth.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305557434/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers17.7.2026 19:10:00 CEST | Press release
Rapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolioBoth INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody, are being evaluated in ongoing Phase 3 programs as first-line treatments for patients with advanced pancreatic ductal adenocarcinoma (PDAC) and microsatellite stable (MSS) colorectal cancer, respectively Incyte (Nasdaq:INCY) today announced that it will highlight data from several programs in its oncology portfolio in six presentations at the European Society of Medical Oncology (ESMO) Congress 2026, being held October 23 - 27, 2026, in Madrid. “The data at ESMO will further illustrate Incyte’s commitment to advancing innovation for patients with cancer,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "Among the presentations are important updates from our KRAS G12D inhibitor in advanced pancreatic ca
STL Expands Its Optical Connectivity Portfolio in the US with the CONCAT Solution17.7.2026 14:24:00 CEST | Press release
STL Optical Connectivity NA, LLC, (STLOC), a U.S. subsidiary of STL (Sterlite Technologies Ltd.) [NSE: STLTECH], a leading connectivity solutions provider for AI-ready digital infrastructure, today announced that it launched its new advanced FTTH solution, CONCAT, after successfully completing field trials on the networks of one of the largest telecom service providers in the United States. Following successful field validation, CONCAT is now available to digital infrastructure providers seeking faster fiber rollouts with reduced deployment complexity and labor. It enables up to 71% in labor cost savings by eliminating most field splicing through factory-assembled, pre-connectorized fiber segments that deliver plug-and-play installation. CONCAT simplifies fiber deployment by shifting critical fiber preparation and termination into a controlled manufacturing environment ensuring consistent quality, faster installation, and lower operational risk in the field. CONCAT solution is ideal fo
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom